{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:59:56Z","timestamp":1786978796678,"version":"build-2736575974"},"reference-count":38,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0The classical myeloproliferative neoplasms (MPNs) are driven by somatic variants in\u00a0Janus kinase 2\u00a0(JAK2),\u00a0calreticulin\u00a0(CALR) and\u00a0thrombopoietin receptor\u00a0(MPL) genes. The heterogeneity in mutational frequency of\u00a0JAK2, CALR, MPL\u00a0and triple-negative MPNs between regions indicates that epidemiological studies in sub-Saharan Africa are required.\nObjective:\u00a0The aim of this study was to describe the genetic variants seen in MPNs at a South African tertiary hospital.\nMethods:\u00a0A retrospective study was conducted at Tygerberg Hospital, Western Cape Province, South Africa. Patients investigated for a classical MPN driver variant (polycythaemia vera [PV], primary myelofibrosis [PMF] and essential thrombocythaemia [ET]) from 2009 to 2020 were included in the study. The associated MPN diagnosis was sought from full blood count and bone marrow reports.\u00a0Janus kinase 2-positive and -negative groups were compared for each MPN using a two-tailed independent samples\u00a0t-test.\nResults:\u00a0There were 128 patients diagnosed with an MPN over the 12-year study period. Polycythaemia vera was the most prevalent (38%), followed by PMF (33%), essential thrombocythaemia (20%), and MPN unclassifiable (9%). The most frequent variant was\u00a0JAK2\u00a0p.V617F (78%) followed by\u00a0CALR\u00a0variants (8%). No\u00a0MPL\u00a0variants were detected among the patients tested. In PMF, patients with\u00a0JAK2\u00a0p.V617F variants were older (mean age 65 years vs 58 years,\u00a0p\u00a0= 0.048) and had a higher haemoglobin (10.6 g\/dL vs 8.1 g\/dL,\u00a0p\u00a0= 0.013) at diagnosis when compared to patients without\u00a0JAK2\u00a0p.V617F.\nConclusion:\u00a0These data suggest that there are differences with regard to MPN epidemiology and variant frequency in South Africa, and further clinical studies are required to fully characterise MPNs in the South African context.\nWhat this study adds:\u00a0This retrospective study expanded the profiling of MPNs and driver variants of MPNs in a South African population. Primary myelofibrosis made up a higher percentage of MPN cases than reported in international studies. In addition, in PMF and essential thrombocythaemia,\u00a0JAK2\u00a0p.V617F was more common and\u00a0CALR\u00a0variants were less common than reported internationally, while\u00a0MPL\u00a0variants were not detected.<\/jats:p>","DOI":"10.4102\/ajlm.v15i1.2965","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:04:33Z","timestamp":1786975473000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutational landscape of classical myeloproliferative neoplasms in the Western Cape Province, South Africa"],"prefix":"10.4102","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0834-3115","authenticated-orcid":false,"given":"Marthinus J.","family":"Dicks","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-3210","authenticated-orcid":false,"given":"Erica-Mari","family":"Nell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3344-5546","authenticated-orcid":false,"given":"Carmen","family":"Swanepoel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6152-5730","authenticated-orcid":false,"given":"Ibtisam","family":"Abdullah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5489-8392","authenticated-orcid":false,"given":"Zivanai C.","family":"Chapanduka","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref0","unstructured":"Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: WHO Press. Lyon: International Agency for Research on Cancer, 2017; p. 39\u201359."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667\u2013679. https:\/\/doi.org\/10.1182\/blood-2016-10-695940","DOI":"10.1182\/blood-2016-10-695940"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Zoi K, Cross NCP. Genomics of myeloproliferative neoplasms. J Clin Oncol. 2017;35(9):947\u2013954. https:\/\/doi.org\/10.1200\/JCO.2016.70.7968","DOI":"10.1200\/JCO.2016.70.7968"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21(9):1960\u20131963. https:\/\/doi.org\/10.1038\/sj.leu.2404810","DOI":"10.1038\/sj.leu.2404810"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u20132390. https:\/\/doi.org\/10.1056\/NEJMoa1311347","DOI":"10.1056\/NEJMoa1311347"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: Relevance for disease evolution. Leukemia. 2015;29(1):249\u2013252. https:\/\/doi.org\/10.1038\/leu.2014.270","DOI":"10.1038\/leu.2014.270"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Mej\u00eda-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000\u20132018. BMC Cancer. 2019;19:590. https:\/\/doi.org\/10.1186\/s12885-019-5764-4","DOI":"10.1186\/s12885-019-5764-4"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cattaneo D, Croci GA, Bucelli C, et al. Triple-negative essential thrombocythemia: Clinical-pathological and molecular features. A single-center cohort study. Front Oncol. 2021;11:637116. https:\/\/doi.org\/10.3389\/fonc.2021.637116","DOI":"10.3389\/fonc.2021.637116"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Chia YC, Islam MA, Hider P, et al. The prevalence of TET2 gene mutations in patients with BCR-ABL-negative myeloproliferative neoplasms (MPN): A systematic review and meta-analysis. Cancers (Basel). 2021;13(12):3078. https:\/\/doi.org\/10.3390\/cancers13123078","DOI":"10.3390\/cancers13123078"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Lee J, Godfrey AL, Nangalia J. Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. Blood Rev. 2020;42:100708. https:\/\/doi.org\/10.1016\/j.blre.2020.100708","DOI":"10.1016\/j.blre.2020.100708"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Shammo JM, Stein BL. Mutations in MPNs: Prognostic implications, window to biology, and impact on treatment decisions. Hematology. 2016;2016(1):552\u2013560. https:\/\/doi.org\/10.1182\/asheducation-2016.1.552","DOI":"10.1182\/asheducation.V2016.1.552.088349"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062\u20131069. https:\/\/doi.org\/10.1182\/blood-2014-05-578435","DOI":"10.1182\/blood-2014-05-578435"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kourie HR, Ameye L, Paesmans M, Bron D. Improved survival of calreticulin-mutated patients compared with Janus Kinase 2 in primary myelofibrosis: A meta-analysis. Clin Lymphoma Myeloma Leuk. 2016;16(5):264\u2013268. https:\/\/doi.org\/10.1016\/j.clml.2016.01.009","DOI":"10.1016\/j.clml.2016.01.009"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Choudhury A, Ramsay M, Hazelhurst S, et al. Whole-genome sequencing for an enhanced understanding of genetic variation among South Africans. Nat Commun. 2017;8(1):2062. https:\/\/doi.org\/10.1038\/s41467-017-00663-9","DOI":"10.1038\/s41467-017-00663-9"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) \u2013 A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Chatambudza M, Skhosana L, Ketseoglou I, Wiggill T. High risk Janus Kinase 2 V617F allele burden in a seven-year cohort of patients with myeloproliferative neoplasms. Clin Lab. 2021;67(11):2509\u20132516. https:\/\/doi.org\/10.7754\/Clin.Lab.2021.210236","DOI":"10.7754\/Clin.Lab.2021.210236"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006;107(10):4139\u20134141. https:\/\/doi.org\/10.1182\/blood-2005-09-3900","DOI":"10.1182\/blood-2005-09-3900"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Soliman EA, El-Ghlban S, El-Aziz SA, Abdelaleem A, Shamaa S, Abdel-Ghaffar H. JAK2, CALR, and MPL mutations in Egyptian patients with classic Philadelphia-negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2020;20(10):e645\u2013e651. https:\/\/doi.org\/10.1016\/j.clml.2020.05.011","DOI":"10.1016\/j.clml.2020.05.011"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Ibrahim IK, Hassan R, Ali EW, Omer A. Polycythaemia Vera among Sudanese patients with special emphasis on JAK2 mutations. Asian Pac J Cancer Prev. 2019;20(1):41\u201344. https:\/\/doi.org\/10.31557\/APJCP.2019.20.1.41","DOI":"10.31557\/APJCP.2019.20.1.41"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Eldeweny S, Ibrahim H, Elsayed G, Samra M. MPL W515 L\/K mutations in myeloproliferative neoplasms. Egypt J Med Hum Genet. 2019;20(1):1\u20137. https:\/\/doi.org\/10.1186\/s43042-019-0039-9","DOI":"10.1186\/s43042-019-0039-9"},{"key":"ref20","unstructured":"Ebid GT, Ghareeb M, Salaheldin O, Kamel MM. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. Int J Clin Exp Pathol. 2015;8(9):11555\u201311559."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Abkar HM, Mohamed BA, Hassan FM, Ricardo P, Zen G. The prevalence of JAK2-V617F mutation in Sudanese patients with chronic myeloproliferative neoplasms. Br J Med Med Res. 2016;14(5):1\u20137. https:\/\/doi.org\/10.9734\/BJMMR\/2016\/24741","DOI":"10.9734\/BJMMR\/2016\/24741"},{"key":"ref22","unstructured":"Sassi H, Menif S, Ammar SB, Farrah A, Othmen HBH, Amouri H. JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation. Pan Afr Med J. 2021;39:194. https:\/\/doi.org\/10.11604\/pamj.2021.39.194.28307"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Benguella-Benmansour M, Boucherit K, Benchikh N, et al. Prevalence of JAK2 V617F mutation in west Algerian population with chronic myeloproliferative neoplasms: A multicenter study. J Afr Cancer. 2014;6(3):138\u2013144. https:\/\/doi.org\/10.1007\/s12558-014-0304-7","DOI":"10.1007\/s12558-014-0304-7"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ojeda MJ, Brag\u00f3s IM, Calvo KL, Williams GM, Carbonell MM, Pratti AF. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology. 2018;23(4):208\u2013211. https:\/\/doi.org\/10.1080\/10245332.2017.1385891","DOI":"10.1080\/10245332.2017.1385891"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Lin Y, Liu E, Sun Q, et al. The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Pathol. 2015;144(1):165\u2013171. https:\/\/doi.org\/10.1309\/AJCPALP51XDIXDDV","DOI":"10.1309\/AJCPALP51XDIXDDV"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Wu Z, Zhang X, Xu X, et al. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol. 2014;7:48. https:\/\/doi.org\/10.1186\/s13045-014-0048-6","DOI":"10.1186\/s13045-014-0048-6"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Zhang SJ, Qiu HX, Li JY, Shi JY, Xu W. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay. Int J Lab Hematol. 2010;32(4):381\u2013386. https:\/\/doi.org\/10.1111\/j.1751-553X.2009.01208.x","DOI":"10.1111\/j.1751-553X.2009.01208.x"},{"key":"ref28","unstructured":"Sazawal S, Bajaj J, Chikkara S, et al. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Res. 2010;132:423\u2013427."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Zulkeflee RH, Zulkafli Z, Johan MF, Husin A, Islam MA, Hassan R. Clinical and laboratory features of JAK2 V617F, CALR, and MPL mutations in Malaysian patients with classical myeloproliferative neoplasm (MPN). Int J Environ Res Public Health. 2021;18(14):7582. https:\/\/doi.org\/10.3390\/ijerph18147582","DOI":"10.3390\/ijerph18147582"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Azevedo AP, Silva SN, Reichert A, Lima F, J\u00fanior E, Rueff J. Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. Biomed Rep. 2017;7(4):370\u2013376. https:\/\/doi.org\/10.3892\/br.2017.977","DOI":"10.3892\/br.2017.977"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Yeh YM, Chen YL, Cheng HY, et al. High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. Am J Clin Pathol. 2010;134(2):266\u2013270. https:\/\/doi.org\/10.1309\/AJCPK7KGOWPHYWM0","DOI":"10.1309\/AJCPK7KGOWPHYWM0"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Lieu CH, Shen YJ, Lai WC, Tsai WH, Hsu HC. Prevalence of MPL W515L\/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms. J Chin Med Assoc. 2010;73(10):530\u2013532. https:\/\/doi.org\/10.1016\/S1726-4901(10)70115-5","DOI":"10.1016\/S1726-4901(10)70115-5"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: Comparison of survival and clinical features involving 603 patients. Leukemia. 2011;25(12):1834\u20131839. https:\/\/doi.org\/10.1038\/leu.2011.161","DOI":"10.1038\/leu.2011.161"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Szuber N, Tefferi A. Driver mutations in primary myelofibrosis and their implications. Curr Opin Hematol. 2018;25(2):129\u2013135. https:\/\/doi.org\/10.1097\/MOH.0000000000000406","DOI":"10.1097\/MOH.0000000000000406"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117(10):2813\u20132816. https:\/\/doi.org\/10.1182\/blood-2010-11-316810","DOI":"10.1182\/blood-2010-11-316810"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: Diagnostic and clinical implications. J Mol Diagn. 2010;12(4):425\u2013432. https:\/\/doi.org\/10.2353\/jmoldx.2010.090188","DOI":"10.2353\/jmoldx.2010.090188"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Furtado LV, Weigelin HC, Elenitoba-Johnson KSJ, Betz BL. Detection of MPL mutations by a novel allele-specific PCR-based strategy. J Mol Diagn. 2013;15(6):810\u2013818. https:\/\/doi.org\/10.1016\/j.jmoldx.2013.07.006","DOI":"10.1016\/j.jmoldx.2013.07.006"}],"container-title":["African Journal of Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/ajlmonline.org\/index.php\/ajlm\/article\/view\/2965\/3628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:04:43Z","timestamp":1786975483000},"score":1,"resource":{"primary":{"URL":"https:\/\/ajlmonline.org\/index.php\/ajlm\/article\/view\/2965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/ajlm.v15i1.2965","relation":{},"ISSN":["2225-2002","2225-2010"],"issn-type":[{"value":"2225-2002","type":"print"},{"value":"2225-2010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"a2965"}}